Introduction
Neointimal formation, defined as thickening of the intimal layer, is a pivotal pathophysiological process that contributes to atherosclerosis, restenosis, and a number of vascular disorders. 1, 2 Accumulating evidence suggests that migration and proliferation of vascular smooth muscle cells (VSMCs) are key processes in neointimal formation. 1, 3, 4 In response to vascular injury and other stimuli, VSMCs lose contractile function and switch to a high-proliferation and high-migration phenotype, thereby expediting the vascular remodelling and occlusion. 1 It is of great importance to understand the molecular mechanisms underlying VSMCs migration, proliferation and neointimal formation to develop effective treatments for related vascular disorders. Semaphorin3E (Sema3E) is one member of the class 3 semaphorins; it binds to its receptor (plexinD1) to activate downstream pathways. 5 Accumulating studies show that the Sema3E/plexinD1 axis plays a pivotal role in guiding development patterns of vasculature in both zebrafish 6, 7 and mice. 5, [8] [9] [10] [11] Inactivation of PlexinD1 in mice embryos leads to congenital heart diseases, absence or atresia of left carotid arteries and less VSMCs coverage of aortic arch arteries. 10, 11 These findings suggest that Sema3E/plexinD1 might be functionally associated with VSMCs. Sema3E/plexinD1 has been found to be a critical regulator of cell migration and proliferation in many scenarios, such as tumor progression, 12 immune-inflammatory disorders, 13 neurological conditions, 14 and airway remodeling. 15 Moreover, it has been shown to regulate macrophage migration during atherosclerosis 16 and dietary obesity. 17 However, its role in VSMCs migration and proliferation during neointimal formation remains poorly understood. In this study, Sema3E was found to be significantly decreased after vascular injury and to be able, via plexinD1 receptor, to inhibit VSMCs migration, proliferation, and to reduce neointimal formation. The inhibitory effect was mediated, at least in part, by inactivating Rap1-AKT signalling pathways in VSMCs. Moreover, we found that Sema3E and PDGF-BB could inhibit the expression of each other, and the mutual inhibition between PDGF-BB and Sema3E after vascular injury played a critical role in neointimal formation.
Methods
A detailed description of the methods is included in Supplementary material online.
Mouse carotid artery ligation-injury model and lentiviral gene transfer
All experimental procedures involving animals were performed in accordance with the Guide for the Care and Use of Laboratory Animals (NIH Publication, 8th edition, 2011) and were approved by the institutional animal care and use committee, the medical ethics committee of Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
Twelve-week-old male C57BL/6 mice (20-25 g) were anesthetized by intra-peritoneal injection of pentobarbital sodium (30-50 mg/kg). The adequacy of anesthesia was evaluated by the absence of response to foot squeezing during the surgery. The left common carotid artery was dissected and completely ligated with a 6-0 silk suture near its bifurcation as described previously. 18 Contralateral common carotid arteries that underwent a similar operation without ligation served as sham controls. After ligation, the mice were euthanatized with an overdose of intra-peritoneal pentobarbital sodium (100 mg/kg) 7, 14, 28 days after experiments. The carotid arteries were harvested. For lentiviral transfection after the left common carotid artery was ligated, 50 mL pluronic F127 gel (BASF, 25%wt/vol) containing LV-Sema3E or LV-GFP was applied around the carotid artery. Carotid arteries were harvested 28 days after the surgery. Animals were anesthetized and perfused with 0.9% NaCl. The ligated and contralateral intact arteries were then isolated for morphometry, qRT-PCR, and Western blot analysis. For morphometric analysis, arteries were fixed with 4% paraformaldehyde and paraffin-embedded for sectioning. Sections were subjected to haematoxylin/eosin (H&E) and immunofluorescence staining.
Human tissue samples
Normal artery samples were acquired from organ transplant donors. Samples of human atherosclerotic arteries were collected from patients undergoing carotid endarterectomy. All procedures involving human samples were approved by an ethics committee of Wuhan Union Hospital and in strict accordance with the standards of the Declaration of Helsinki. Informed consent was obtained from all participating patients. All human specimens were fixed with 4% paraformaldehyde and embedded in paraffin.
Statistical analysis
All values were expressed as mean ± SD. SPSS, v13 software package (IBM, Armonk, NY, USA) was used for statistical analysis. Statistical differences were evaluated by employing the Student's t test for two-group comparison or one-way ANOVA for multiple-group comparison, followed by a post hoc S-N-K test whenever necessary. The correlations between Sema3E and PDGFB in human atherosclerotic plaques were determined by Spearman's rank test. P < 0.05 was considered to be statistically significant.
Results

Sema3E expression is decreased in VSMCs during neointimal hyperplasia
As the expression of Sema3E in vessel walls remains unknown, we first investigated the presence of Sema3E in mice and human arteries.
Immunofluorescence staining showed that Sema3E was expressed in alpha-smooth muscle actin (a-SMA)-positive VSMCs of mouse ( Figure  1A ) arteries under normal conditions. By employing a model of neointimal hyperplasia, we investigated if the content of Sema3E experiences changes during vascular remodelling. As shown in Figure 1A , after artery ligation, immunofluorescence staining indicated the expression of Sema3E was markedly decreased in VSMCs at day 14 and day 28. Moreover, qRT-PCR and Western blotting revealed that the mRNA and protein levels of Sema3E were progressively down-regulated 7, 14, and 28 days after carotid artery ligation ( Figure  1B-D) .
Neointimal hyperplasia is a pivotal pathophysiological process that contributes to atherosclerosis. 19 To know whether Sema3E expression also undergoes changes during neointimal hyperplasia in the development of human atherosclerosis, we analysed the expression pattern in human carotid arteries with atherosclerotic plaques. As shown in Figure  1E , Sema3E was substantially reduced in a-SMA 1 VSMCs of human carotid atherosclerotic segments. Furthermore, we also determined the expression pattern of Sema3E in mice atherosclerotic plaques by using an Apoe -/-mice model.
Consistent with previous findings, immunofluorescence staining showed that Sema3E was markedly deceased in VSMCs of atherosclerotic plaques as compared with the normal aortic arteries (see Supplementary material online, Figure S2A ). Moreover, the levels of Sema3E mRNA and protein levels were significantly lower in aortic arteries with atherosclerotic lesions in Apoe -/-mice on a high-fat diet for 12 weeks, compared with levels in age-matched Apoe -/-mice on a normal diet (see Supplementary material online, Figure S2B -D).
Expression of PlexinD1 receptor by VSMCs
Previous studies have shown that Sema3E binds plexinD1 receptor to regulate downstream signalling pathways in the control of vascular patterning. 5, 7 Immunofluorescence staining showed that plexinD1 was predominantly co-localized with a-SMA 1 VSMCs in both intact and ligated carotid arteries (Figure 2A ).
Sema3E suppresses neointimal hyperplasia in vivo
To further investigate whether Sema3E affects neointimal hyperplasia in vivo, we used lentivirus to overexpress Sema3E (LV-Sema3E) in the Figure S3A ). Twenty-eight days after transfection, Western blotting showed that the expression of Sema3E in ligated carotid arteries transfected with LV-Sema3E was substantially increased when compared with the LV-GFP transfection group (see Supplementary material online, Figure S3B and C). Figure 2B shows that LV-Sema3E strongly inhibited the neointimal formation as compared with LV-GFP ( Figure 2B ) and such an inhibitory effect was associated with a decrease in both the neointimal area ( Figure  2C ) and the intima/media ratio ( Figure 2D ). Furthermore, immunostaining of Ki67 in carotid arteries showed that the Ki67-positive cells in neointima were significantly decreased in LV-Sema3E-transfected arteries as compared with their LV-GFP-transfected counterparts ( Figure 2E and F). 
Sema3E inhibits VSMCs migration and proliferation via PlexinD1 receptor
VSMCs migration and proliferation are key cellular events in neointimal hyperplasia.
1,3 Therefore, we further explored the role of Sema3E on VSMCs migration and proliferation. First, we performed the transwell migration assay to observe the effect of Sema3E on VSMCs migration. VSMCs were treated with different concentrations of recombinant Sema3E in the presence of PDGF-BB (20 ng/mL), a well-known potent stimulator of VSMCs migration and proliferation, 2 and after 6 h, the migrated cells were counted. Figure 3A and B show that Sema3E inhibited VSMCs migration in a dose-dependent manner. We used a short hairpin RNA (shRNA) for plexinD1 (sh-plexinD1) to decrease the expression of plexinD1 in VSMCs ( Figure 3C and D) and found that sh-plexinD1 reversed the inhibitory effect of Sema3E on VSMCs migration ( Figure 3E ). Consistently, the wound closure assay, with cell proliferation inhibited with mitomycin-C, also revealed the same inhibitory effect of Sema3E on VSMCs migration (see Supplementary material online, Figure S4A and B).
Mopping up Sema3E with recombinant plexinD1 also reversed the inhibitory effect of Sema3E (see Supplementary material online, Figure S4C and D).
We studied the effect of Sema3E on VSMCs proliferation by using Ki-67 (a marker for proliferating cells) immunofluorescence staining. The number of Ki-67-positive cells was reduced in a dose-dependent manner following treatment with recombinant Sema3E ( Figure 3G ). Moreover, we found that recombinant Sema3E significantly blocked cell-cycle progression from G 0 /G 1 phase into S phase ( Figure 3J and K) . Meanwhile, the anti-proliferative effect of Sema3E was abolished by either sh-plexinD1 ( Figure 3H -K) or recombinant plexinD1 (see Supplementary material on line, Figure S4E -H). To further support our findings, we conducted a gain-of-function study using lentivirus-mediated over-expression of Sema3E (LV-Sema3E). Transfection of VSMCs with LV-Sema3E resulted in an increased expression of Sema3E (see Supplementary material on line, Figure S4I-K) . The growth curve change shows that over-expression of Sema3E also effectively suppressed the proliferation of VSMCs in the presence or absence of 20 ng/mL PDGF-BB ( Figure 3F) .
Collectively, these data suggest that Sema3E could inhibit VSMCs migration and proliferation through plexinD1 receptor.
Sema3E inactivates Rap1-Akt signalling pathways to suppress VSMCs migration and proliferation
We explored the molecular mechanisms of Sema3E inhibiting VSMC functions. It has been extensively reported that Akt and ERK1/2 signalling pathways play important roles in the migration and proliferation of VSMCs. 20, 21 Therefore, the phosphorylation levels of Akt and ERK1/2 in VSMCs were examined in our study. As shown in Figure 4A and B, pretreatment with recombinant Sema3E evidently reduced PDGF-BB induced phosphorylation of Akt but not ERK1/2 and the effect was neutralized by pre-treatment with recombinant plexinD1. Meanwhile, Over-expression of Sema3E (LV-Sema3E) also inhibited phosphorylation of Akt in the presence of PDGF-BB ( Figure 4C and D) . We used a specific siRNA to silence Sema3E (see Supplementary ma terial online, Figure S5J -L) and a specific Akt inhibitor 22 (MK-2206 2HCl)
to block Akt signalling pathway ( Figure 4E -I) in VSMCs. We found that knock-down of Sema3E moderately induced phosphorylation of Akt ( Figure 4E and F) . Moreover, silencing Sema3E also enhanced the migration and proliferation of VSMCs, whereas MK-2206 entirely abrogated the effect ( Figure 4G-I) .
A recent study reported that the plexin cytoplasmic regions had selective GTPase activating protein (GAP) activity on Rap1 signalling pathway in neuronal cone collapse. 23 Moreover, Rap1-GTP could directly bind to phosphatidylinositol 3-Kinase (PI3K) and activate the PI3K/Akt pathway in neurons. 24 Subsequently, we examined whether Sema3E decreases phosphorylation of Akt through Rap1 signalling pathway. We found that PDGF-BB stimulation rapidly increased Rap1-GTP activation at 5 min and over-expression of Sema3E evidently decreased the Rap1-GTP activation in the presence or absence of PDGF-BB ( Figure 4J and K).
We conducted a rescue experiment by overexpressing a constitutively active Rap1 mutant (Rap1E63 23, 25 ) (see Supplementary material online, Figure S5A ). Figure 4L and M show that the Sema3E-induced de-phosphorylation of Akt was blocked after Rap1E63 vector transfection. Moreover, transfection with Rap1E63 vector virtually abrogated the inhibitory effect of Sema3E on VSMC migration and proliferation ( Figure  4N and O) .
The matrix metalloproteinases, such as MMP-2, MMP-9, are known to be centrally involved in VSMCs migration during vascular remodelling 26 and atherosclerotic progression. 27 Compared with PDGF-BB treatment alone, combination of recombinant Sema3E with PDGF-BB markedly decreased the mRNA and protein levels of MMP-2, MMP-9 in VSMCs (see Supplementary material online, Figure S5B -F) and the recombinant plexinD1 protein could reverse the effect. Moreover, downregulation of Sema3E increased the expression of MMP-2, MMP-9, and the effect was completely abolished by Akt inhibitor MK-2206 (see Supplementary ma terial online, Figure S5G -I).
These results suggest that Sema3E could inhibit VSMC migration and proliferation by inactivating Rap1-AKT signalling pathway.
PDGF-BB decreases the expression of Sema3E in VSMCs through p53 in vitro
Next, we sought to identify the mechanism that down-regulates Sema3E expression in VSMCs. Figure 5A -C indicate that PDGF-BB decreased mRNA and protein levels of Sema3E in a dose-dependent fashion, showing a significant effect at 20 ng/mL. Figure 5D -F show the mRNA and protein levels of Sema3E were also decreased in a time-dependent manner when VSMCs were treated with 20 ng/mL PDGF-BB. Since Sema3E is a secretory protein, we examined the expression of Sema3E in a conditioned medium of VSMCs, treated with 20 ng/mL PDGF-BB for 36 h, and found that secretory Sema3E protein was evidently decreased in the conditioned medium (see Supplementary material online, Figure S6A and B).
Previous evidence showed that another Semaphorin (Semaphorin3F) was upregulated by p53 in cancer cells, thereby resulting in tumor suppression. 28 We found that PDGF-BB treatment decreased p53 expression ( Figure 5G and H, see Supplementary material online, Figure S6C ). Pifithrin-a, a p53 transcriptional activation inhibitor, 29 decreased the mRNA and protein levels of Sema3E in VSMCs under normal conditions ( Figure 5I and J, see Supplementary material online, Figure S6D ). Moreover, overexpression of p53 significantly induced Sema3E expression and rescued Sema3E inhibition by PDGF-BB treatment ( Figure 5K and L, see Supplementary material online, Figure S6E -G).
Correspondently, bioinformatic analyses (http://jaspar.genereg.net) identified a putative p53 binding site in the promoter region of Sema3E ( Figure 5M ). ChIP assays confirmed that PDGF-BB stimulation reduced the recruitment of p53 to the Sema3E promoter as compared to the control VSMCs ( Figure 5M ).
Semaphorin-3E inhibits VSMCs migration and proliferation during neointimal formation (n = 5, *P < 0.05 compared with sh-GFP group). (E) Migration assays using VSMCs infected with sh-plexinD1 or sh-GFP in the presence or absence of 500 ng/mL recombinant Sema3E. (n = 7, *P < 0.05 compared with sh-GFP group, NS means no statistical significance).
(F) LV-Sema3E-induced Sema3E over-expression significantly inhibited the growth of VSMCs compared with LV-GFP in presence or absence of PDGF-BB (20 ng/mL) by CCK8 assays (n = 6, *P < 0.05 compared between LV-GFP and LV-Sema3E, † P < 0.05 compared between LV-GFP/PDGF and LV-Sema3E/ PDGF at each time point by the Student's t test). (G) Recombinant Sema3E (ng/mL) dose-dependently decreased PDGF-BB (20 ng/mL)-induced VSMCs proliferation (Ki67 staining) (n = 6, *P < 0.05 compared with only PDGF-BB treatment group). (H and I) Ki67 immunofluorescence staining assays using VSMCs infected with sh-plexinD1 or sh-GFP in the presence or absence of 500 ng/mL recombinant Sema3E. (n = 6, *P < 0.05 compared with sh-GFP group, NS means no statistical significance). Bars indicate 150 lm. (J and K) Sema3E arrested cell-cycle progression from G 0 /G 1 phase into S phase, and the effect was abrogated by plexinD1 knockdown (Flow Cytometry). Percentage of cells in S-phase was quantified (n = 5, *P < 0.05 compared with sh-GFP group, NS means no statistical significance). 
Over-expression of Sema3E reduces the availability of PDGF-B
As shown in Figure 6A and B, we incidentally found LV-Sema3E transfection decreased the expression of PDGF-BB in ligated carotid arteries. PDGFB, released by both endothelial cells and VSMCs, 2 plays a critical role in neointimal formation after vascular injury. Immunofluorescence staining showed that plexinD1 was expressed in the carotid endothelial layer ( Figure 6F ). To clarify which cells mediated this effect of Sema3E, endothelial cells and VSMCs were treated with recombinant Sema3E, respectively. Recombinant Sema3E only slightly inhibited the expression of PDGFB in VSMCs ( Figure 6C-E) . However, it notably inhibited the mRNA and protein levels of PDGFB in endothelial cells in a dosedependent manner, and the effect could be reversed by recombinant plexinD1 protein ( Figure 6G-I) . Egr-1 is a vital transcription factor that directly regulates PDGFB expression in vascular cells. 30 We found that recombinant Sema3E reduced Egr-1 expression in endothelial cells in a time-dependent manner ( Figure 6J) . Overexpression of Egr-1 ( Figure 6K ) significantly abrogated Sema3E-induced inhibition of PDGFB expression ( Figure 6L ).
A negative correlation exists between Sema3E and PDGFB in human atherosclerotic plaques
We demonstrated a reversal expression pattern of Sema3E and PDGF-BB after vascular injury in mice. However, no reports were found regarding the relationship between Sema3E and PDGF-BB in atherosclerosis patients. Results from a public GEO microarray database exhibited an opposite expression pattern of Sema3E and PDGFB in human atherosclerotic plaques ( Figure 7A-D) . Moreover, a negative correlation existed between Sema3E and PDGFB transcript levels in human specimens ( Figure 7E and F).
Discussion
In the present study, we demonstrated that: (i) the expression of Sema3E in VSMCs was progressively decreased during neointimal hyperplasia and was down-regulated in human atherosclerotic arteries; (ii) replenishment of Sema3E caused a significant reduction of neointimal hyperplasia; (iii) Sema3E inhibited VSMCs migration and proliferation, at least in part, by inactivating Rap1-AKT signalling pathways; (iv) Sema3E and PDGF-BB could mutually inhibit the expression of each other, and converse inhibition of Sema3E and activation of PDGF-BB after vascular injury could form a positive feedback loop that accelerated neointimal formation; (v) a negative correlation between Sema3E and PDGFB was found in the human plaque specimens. To our best knowledge, this is the first time that Sema3E has been found to be decreased after vascular injury and to be able, via plexinD1 receptor, to inhibit VSMCs migration, proliferation, and to reduce neointimal formation. Sema3E has been found to play an important role in cancer invasiveness, 12 dietary obesity 17 and asthma 15 through regulating cell migration and proliferation. VSMC proliferation and migration are key issues in neointimal formation during atherosclerosis and restenosis, 1, 3 which is not completely understood. In our study, we found that Sema3E was markedly decreased in VSMCs during the neointimal formation in mice and human plaque specimens. However, a previous study 16 found that Sema3E expression in macrophages was down-regulated during atherosclerosis regression as compared with progression environment. It should be noted that this study focuses only on CD68 þ macrophages during atherosclerosis regression. It is possible that the expression profile of Sema3E varies with cell types in different periods due to the complexity of atherosclerotic process. Moreover, our study revealed that replenishment of Sema3E led to an evident decrease of neointimal formation, indicating Sema3E as a critical inhibitor of neointimal formation. We found that Sema3E inhibited VSMCs migration and proliferation. Sema3E is different from other Semaphorins in that it directly binds to PlexinD1 and does not require co-receptor to exert its effect. 5 Previous studies demonstrated that the plexinD1 receptor alone mediated antimigratory effects of Sema3E on macrophages 16 during atherosclerosis and on human airway smooth muscle cells 15 during airway remodelling.
However, another study indicated that Sema3E could act as a chemoattractant for macrophages via PlexinD1/Nrp1/VEGFR2 complex during dietary obesity. 17 Hence, different receptor complexes mediate dual roles of Sema3E on cell migration. In our study, the inhibitory effect of Sema3E on VSMCs migration and proliferation was virtually abrogated by silencing plexinD1 or recombinant plexinD1, suggesting that Sema3E exerts its inhibitory effect on VSMCs through the plexinD1 receptor alone. Additionally, our study showed that plexinD1 was evidently stained in VSMCs of both intact and ligated carotid arteries, implying that diminished Sema3E/PlexinD1 signalling during neointimal hyperplasia may be attributed to Sema3E down-regulation. Mechanistically, we found that Sema3E inactivated Rap1-Akt signalling pathways to suppress VSMCs migration and proliferation. Mounting evidence 31, 32 indicated that Rap1 signalling was an important regulator in the cardiovascular system. It was reported that Rap1 signalling could regulate adrenoceptors translocation to the cell surface of VSMCs to control vasoconstriction 31 and an immediate activator of Rap1 (Epac) could induce VSMCs migration. 32 Our results showed that Sema3E significantly decreased PDGF-BB-induced Rap1-GTP activation and Akt phosphorylation. Overexpressing a constitutively active Rap1 mutant (Rap1E63) practically abrogated the inhibitory effect of Sema3E on VSMCs migration, proliferation and Akt phosphorylation. The results suggest that Rap1 inactivation is critical for the inhibitory effect of Sema3E. A recent study reported that the plexin cytoplasmic regions could directly inactivate Rap1-GTP by catalyzing hydrolysis of the bound GTP to GDP in neuronal cone collapse when stimulated by semaphorin. 23 Moreover, Rap1-GTP could directly bind to phosphatidylinositol 3-Kinase (PI3K) and activate PI3K/Akt pathway in neuron. 24 Meanwhile, our results also showed that Sema3E inactivated Rap1-GTP and inhibited VSMCs proliferation and migration in the absence of PDGF-BB. These findings suggest that Sema3E/PlexinD1 may relay the signal to downstream pathways directly by inactivating Rap1-GTP in VSMCs.
The matrix metalloproteinases such as MMP-2, MMP-9, are known to be critically involved in VSMCs migration during vascular remodelling 26 and atherosclerotic progression. 27 We found that Sema3E treatment significantly down-regulated MMP-2 and MMP-9 expression in VSMCs. The findings indicate that MMP-2 and MMP-9 are involved in Sema3E-mediated inhibition of VSMCs migration. PDGFB is the most potent mitogen for VSMCs, can critically drive their migration, [33] [34] [35] [36] and is principally produced by activated endothelial cells and VSMCs after vascular injury. 2 Our study revealed that Sema3E expression was reduced by PDGF-BB in cultured VSMCs. More importantly, we found that PDGF-BB reduced the recruitment of p53 to the Sema3E promoter, thereby inhibiting Sema3E transcription in VSMCs.
These results are consistent with the previous studies that p53 could induce Sema3E expression during dietary obesity 17 and hind-limb Semaphorin-3E inhibits VSMCs migration and proliferation during neointimal formation ischaemia. 37 In particular, p53 was reported to serve as a critical regulator of VSMCs proliferation and neointimal formation during vascular injury. [38] [39] [40] Thus, p53-induced Sema3E expression could account for the suppressive effect of p53 on neointimal hyperplasia. Interestingly, our data also demonstrated that Sema3E inhibited the expression of PDGFB in endothelial cells via Egr-1, a vital transcription factor that directly regulates PDGFB expression in vascular cells. 30 Given that PDGF-BB substantially down-regulated Sema3E in VSMCs, we believe that mutual inhibition between PDGF-BB and Sema3E after vascular injury forms a positive feedback loop that goes as follows ( Figure  8 ): under normal conditions, Sema3E is abundantly expressed in the vascular wall. After vascular injury, endogenous and exogenous stimuli result in up-regulation of PDGFB 41 and down-regulation of Sema3E in the injured arteries. Moreover, increased PDGFB in the injured arteries could down-regulate the expression of Sema3E in VSMCs, which in turn leads to a greater increase in PDGFB, thereby promoting the neointimal formation. Thus, Replenishment of Sema3E could inhibit not only VSMC migration and proliferation but also the expression of PDGFB to block the circuit, thereby attenuating neointimal formation. A search of public GEO microarray databases demonstrated that Sema3E transcription was negatively correlated with PDGFB transcription in human plaques, which further supports such mutual inhibition.
Although our study shows a mutual inhibition between PDGF-BB and Sema3E during neointimal formation, the initial step activated by vascular injury is beyond the scope of this study. Though immunofluorescence detection demonstrates that Sema3E was evidently stained in intima of normal carotid arteries, the staining was weaker after vascular injury ( Figure 1A) . The results suggest that both endothelial cells and VSMCs may contribute to the decrease in Sema3E during neointimal hyperplasia. Meanwhile, endothelial cells-derived Sema3E could also affect VSMCs function in a paracrine manner. A previous study 42 indicated that another neuronal guidance molecule semaphorin3A was highly expressed in endothelial cells to prevent leucocyte influx under normal condition and was down-regulated under pro-atherosclerotic condition. Since endothelial dysfunction is one of the important initial steps leading to neointimal hyperplasia during atherosclerosis and restenosis, 43 further research effort should be directed at whether vascular injury factors cause an identical change in endothelial cells-derived Sema3E, thereby initiating the feedback loop between Sema3E and PDGF-BB. Additionally, our study detected a single 35 kDa band in the entire carotid artery walls from normal and injured conditions with two different antibodies (ab112886 and ab128619 from Abcam company) (see Supplementary material online, Figure S1 ). Meanwhile, we found that the 35 kDa band could be silenced by Sema3E siRNA and could be Figure 7 The association of Sema3E with PDGFB in human atherosclerotic plaques. (A and B) The Sema3E mRNA levels were lower in human atherosclerotic plaques than those in normal arteries in independent cohorts derived from GEO database (https://www.ncbi.nlm.nih.gov/gds/). (C and D) The PDGFB levels were higher in human atherosclerotic plaques than those in normal arteries in independent cohorts derived from GEO database. (E and F) There was a negative correlation between Sema3E and PDGFB transcript levels in the enrolled samples in independent GEO datasets. The samples were obtained from human carotid arteries in GSE43292 (A, C, E) and GSE24495 (F) datasets. The samples were obtained from human aortas in GSE57691 (B and D) dataset. The bands were consistent with previous studies. 12, 44 So the 35 kDa band in carotid artery walls may be a splice variant of Sema3E, however, the detailed information of different splice variants of Sema3E needs to be further explored in future studies.
Semaphorin-3E inhibits
In conclusion, our study indicates that Sema3E serves as a reparative regulator of neointimal formation, Sema3E inhibits the migration and proliferation of VSMCs via Rap-1-AKT signalling pathway and the feedback circuit between Sema3E and PDGF-BB after vascular injury is of significance in the process of neointimal formation.
Supplementary material
Supplementary material is available at Cardiovascular Research online.
